Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01986348
Title Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karyopharm Therapeutics, Inc
Indications

glioblastoma

Therapies

Selinexor

Age Groups: adult
Covered Countries USA


No variant requirements are available.